In 1973, a Soviet physician named Vladimir Khavinson began administering thymic peptide extracts to elderly patients in St Petersburg. He continued tracking those patients — and subsequent cohorts — for the next five decades. What he found is among the most striking human longevity data in the peptide literature, and among the least known in the West.
The thymus is a small gland located in the upper chest, behind the sternum. Its primary function is the maturation of T-cells — the immune cells responsible for identifying and eliminating pathogens, cancer cells and cellular debris. A functional thymus is essential for a functional adaptive immune system.
The problem is that the thymus begins to atrophy in early adulthood. This process, called thymic involution, is gradual but relentless. By age 40, most people have lost roughly 70% of functional thymic tissue. By 65, the gland is largely replaced by fat. The T-cell output declines accordingly, and with it the capacity for immune surveillance, response to new infections and cancer cell clearance.
This is one reason the elderly are more susceptible to infections, respond less well to vaccines, and have higher cancer incidence — not because the immune system has simply "worn out" but because the gland responsible for producing its most important components has structurally failed.
Thymalin is a polypeptide complex extracted from the thymus glands of young calves. It contains a mixture of biologically active peptides — predominantly thymosin-related compounds — that appear to restore thymic signalling even in aged individuals whose own thymic tissue is substantially involuated.
It is distinct from Thymosin Alpha-1 (a specific, characterised single peptide) in that Thymalin is a complex mixture rather than a single purified molecule. This makes it pharmacologically more complex to characterise but potentially broader in its effects.
Khavinson's most cited study enrolled elderly patients in St Petersburg and administered Thymalin alongside Epithalamin (the source compound from which Epitalon is derived) over a period of years, with a 12-year follow-up. The findings were significant:
Compared to control groups, treated patients showed: 28% reduction in mortality over the 12-year period, significantly lower cancer incidence, maintained immune function as measured by T-cell counts and activity, and preserved bone density and cardiovascular markers.
These are human outcomes data — not animal models, not cell studies. The effect sizes are large enough to be clinically meaningful. The follow-up period is long enough to capture genuine mortality differences.
The study has attracted criticism for its methodology — it was conducted in Russia, published primarily in Russian-language journals, and has not been replicated in the format that Western regulatory science would require for clinical approval. Khavinson's work is not universally accepted and should not be treated as definitive. It is, however, too significant to dismiss.
The proposed mechanism involves restoration of thymic peptide signalling to bone marrow stem cells — encouraging the production of T-cell precursors and supporting their maturation even in the absence of functional thymic tissue. Some research suggests that the peptides in Thymalin can stimulate residual thymic tissue, partially reversing involution.
This aligns with other research on thymic regeneration. A 2021 study (the TRIIM-X trial) showed that a combination of growth hormone, DHEA and metformin produced measurable thymic tissue regrowth in healthy elderly men — the first human demonstration that thymic involution is not necessarily irreversible. Thymalin may be working through overlapping mechanisms.
Thymalin is available as a research compound and is used by longevity practitioners — particularly in Eastern Europe where Khavinson's research has greater mainstream acceptance. Typical use involves periodic administration courses rather than continuous use, based on the idea of stimulating rather than replacing thymic function.
It is not approved for therapeutic use in the UK. No completed Western clinical trials exist. The evidence base is real but not structured in a form that UK or EU regulators would accept for approval. This places it firmly in the category of compounds used by informed self-experimenters operating ahead of the regulatory curve — which is where much of the most interesting longevity research sits.
Enter your email and we'll notify you when we publish something new. Free. No Pep IQ account required. Unsubscribe anytime.
Complete reference entries, protocol guidance and blood work calendars for the compounds in active use.